The Off-Label Use of Selective Serotonin Reuptake Inhibitors for Sexual Behavior Management: Risks and Considerations

    September 2025 in “ Healthcare ”
    Jonathan Shaw, Charles Lai, Peter Bota … Tina Allee
    Studysummary This review discusses the off-label use of SSRIs to manage inappropriate sexual behavior in elderly dementia patients and highlights the unclear risk of post-SSRI sexual dysfunction, noting a need for high-quality clinical trials.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on mdpi.com →
    Discuss this study in the Community →

    Research cited in this study 7

    1. Insights Into the Peripheral Nature of Persistent Sexual Dysfunction Associated With Post-Finasteride, Post-SSRI, and Post-Accutane Syndromes: Lessons Learned From a Case Study International Urology and Nephrology · 2025
    2. Post-Finasteride Syndrome and Post-SSRI Sexual Dysfunction: Two Clinically Similar Conditions Frontiers in Neuroendocrinology · 2023
    3. Estimating the Risk of Irreversible Post-SSRI Sexual Dysfunction Due to Serotonergic Antidepressants Annals of General Psychiatry · 2023
    4. Diagnostic Criteria for Enduring Sexual Dysfunction After Treatment With Antidepressants, Finasteride, and Isotretinoin The international journal of risk and safety in medicine · 2021
    5. Post-Finasteride Syndrome: An Emerging Clinical Problem Neurobiology of Stress · 2019
    6. Neuroactive Steroid Levels and Psychiatric and Andrological Features in Post-Finasteride Patients The Journal of Steroid Biochemistry and Molecular Biology · 2017
    7. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-Analysis PubMed · 2015